Immunoassay-based serology techniques play key roles in many SARS-CoV-2 research programs due to their ability to identify and characterize the immune response of individuals already infected by the virus through analysis of biomarkers such as immunoglobulins.
However, the limited sensitivity and resolution offered by traditional assay platforms and their serology assays can leave crucial research questions unanswered.
We harnessed the power of the SMC® ultrasensitive immunoassay platform to develop SARS-CoV-2-specific antibody assays, which can be used to resolve subtle differences in humoral immunity among individuals and detect antibody response earlier after infection. These assays may also be used to thoroughly profile immune responses after vaccine challenge.
This webinar describes how these new kits were developed by the Custom Assay & Sample Testing (CAST) team, and details the key data from the assay development and verification work, including signal linearity, sensitivity and specificity determination, assay precision, and cross-reactivity.
Products presented in this webinar are For Research Use Only. Not For Use In Diagnostic Procedures.
Speakers
Rosemary Sweetwood
Manager, CAST Sample Testing, Scientist II CAST Custom Assay Development
Merck
Rosemary Sweetwood has worked with SMC® technology for over 7 years in diagnostic development, assay development, and custom manufacturing, as well as managing clinical sample testing projects for our SMC® Sample Testing customers. With almost two decades of research experience working in government research labs (FDA and VA), Academia (UCSF), and Biotech/Pharma (Dynavax, MedImmune/AstraZeneca, Novartis, and Singulex), Rosemary has publications spanning neurology, virology, and immunology. She has also worked in early-phase vaccine research with several vaccines that have gone into clinical trials, and biomarker assay development has been a critical function throughout Rosemary’s career.
Protein biology
- Protein quantitation
期间:2h
语言:English
场次 1:往期 February 22, 2021
如要继续阅读，请登录或创建帐户。
暂无帐户？